© 2022 MJH Life Sciences and Managed Healthcare Executive. All rights reserved.
© 2022 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
A discussion series reviewing the differences between unbranded biologics and biosimilars and an overview of payer and provider considerations for decision-making.
August 10th 2022
Dr David Charles, MD, opens a discussion surrounding the increasing usage and unique characteristics of biologics.
August 17th 2022
Distinctions between unbranded biologics, branded biologics, and biosimilars are explored by David Charles, MD.
August 24th 2022
Dr Charles discusses the clinical impacts that nonmedical switching of biologic treatments can have on quality of patient care.
August 31st 2022
Dr Charles provides his closing insights, focusing on unbranded biologics targeted for pipeline development.
September 9th 2022
Kareem Karara, PharmD, BCPS, CCHP continues this discussion on unbranded biologics, discussing payer priorities for treatment options.
Dr Karara discusses evolution of the biologics space and highlights important regulatory definitions.
September 16th 2022
Differences between biologics – both branded and unbranded – and biosimilars are explored by Dr Karara.
Dr Karara provides insight into how unbranded biologics are impacting the overall treatment landscape.
September 23rd 2022
Study-based findings provide support for considerable implications of multiple switching between biosimilar and originator products.
September 30th 2022
Kareem Karara discusses several factors impacting the affordability of biologics for patient care pathways.